China Pharma Holdings, Inc. — FY2019 Form 10-K
Business context and reporting period. This is the annual report for the year ended December 31, 2019, not a standalone fourth-quarter report. The company develops, manufactures and sells prescription pharmaceuticals and a healthcare product in China; its operations and manufacturing facilities are in Hainan Province. It reported 19 pharmaceutical products and one comprehensive healthcare product.
Financial performance and position
| Metric | FY2019 / December 31, 2019 | Prior comparable period |
|---|---|---|
| Revenue | $10.92 million | $12.33 million in FY2018; down 11.4% |
| Gross profit / margin | $1.48 million / 13.6% | $1.97 million / 16.0% |
| Operating loss | $20.41 million | $10.45 million in FY2018 |
| Net loss / loss per share | $20.70 million / $0.48 | $10.75 million / $0.25 in FY2018 |
| Operating cash flow | $0.61 million provided | $1.88 million provided in FY2018 |
| Cash and cash equivalents | $1.07 million | $1.19 million at December 31, 2018 |
| Total current assets / liabilities | $5.58 million / $10.05 million | Current-liability excess: $4.47 million |
| Construction loan | $4.30 million, split equally between current and non-current portions | $6.54 million at December 31, 2018 |
| Total liabilities / stockholders’ equity | $13.00 million / $9.24 million | At December 31, 2019 |
Cost of revenue fell to $9.44 million from $10.36 million, but rose as a share of revenue to 86.4%, reflecting fixed costs against lower sales. Selling expense declined to $2.35 million from $3.22 million; general and administrative expense increased to $2.29 million from $1.95 million. R&D expense was $0.23 million.
The company recorded a $17.02 million impairment loss in 2019, primarily writing off all advances for pipeline medical formulas; the comparable impairment was $6.48 million in 2018. Inventory declined to $3.59 million from $5.05 million. Net accounts receivable was $0.64 million, against a $17.58 million allowance for doubtful accounts.
Financing cash outflow was $1.73 million, mainly reflecting construction-loan repayments; investing cash outflow was $0.14 million. The CEO and chair advanced $0.69 million during 2019. Cash held by the Chinese subsidiary was described as indefinitely reinvested and not expected to be available to the parent or shareholders. The filing reports no off-balance-sheet arrangements and no cash-dividend plans.
Material changes versus FY2018
- Revenue declined 11.4%; every reported product category decreased. Anti-infection and respiratory products remained the largest category, at $6.33 million, or 58% of revenue.
- Gross margin fell 2.4 percentage points, while operating and net losses widened materially, driven chiefly by the higher impairment charge.
- Operating cash flow fell from $1.88 million to $0.61 million. Restricted cash decreased to $0.11 million from $1.27 million.
- The construction-loan balance declined by about $2.24 million. Total assets fell to $22.24 million from $45.38 million, largely alongside the write-off of intangible-asset advances.
Outlook, risks and unusual items
- Going concern: The auditor’s report highlights substantial doubt about the company’s ability to continue as a going concern, citing recurring operating losses, net current liabilities and accumulated deficit. Management describes plans to increase advance payments and receivable collections, pursue nutrition-product opportunities and potentially borrow against fixed assets. The filing says these plans were not sufficiently finalized or within the company’s control to alleviate the substantial doubt; there is no assurance financing will be available.
- Guidance: No quantified revenue, earnings or margin guidance is provided. Management says operating cash should support needs for the next 12 months under its current plan, but notes this assessment excludes potential COVID-19 impacts.
- Market and regulatory pressure: China’s centralized group purchasing and drug-price controls, consistency-evaluation requirements and lower hospital drug spending are pressuring prices, sales and margins. Failure to meet consistency requirements could restrict products’ eligibility for procurement programs. The revised Drug Administration Law, effective December 1, 2019, replaced GMP certification with ongoing quality-system requirements and pilot inspections that could suspend production lines.
- COVID-19: The report notes temporary facility closures and reduced operations in February–March 2020; work resumption was about 90% by March 25. The eventual effects on operations, demand and cash flow were uncertain.
- Controls and reporting: Management found internal control over financial reporting and disclosure controls ineffective at year-end, identifying a material weakness related to insufficient personnel knowledgeable in U.S. GAAP. Management said it was pursuing training and process improvements. The auditor gave an unmodified opinion on the financial statements, but did not attest to control effectiveness.
- Concentration and other exposures: Two customers represented 49.6% and 10.7% of receivables, although no customer exceeded 10% of sales. Three suppliers accounted for 22.3%, 20.6% and 5.8% of raw-material purchases. The company also cites China-related currency-conversion, regulatory and operating risks, and limited insurance coverage.
Reporting inconsistency to note: In MD&A, the filing describes the 2019 net-loss change as a “decrease” and attributes it to a “decrease” in impairment. The audited financial statements show the opposite: net loss increased to $20.70 million from $10.75 million, and impairment increased to $17.02 million from $6.48 million.
Important facts for investors to verify
- Whether the company can fund operations and meet the $2.15 million construction-loan principal due in 2020, given its $1.07 million cash balance and $4.47 million working-capital deficit.
- Collectability and aging of receivables, including the large allowance, and whether advance-payment and collection initiatives improve cash generation.
- Recoverability, contractual refund rights and any prospect of restarting the impaired medical-formula projects.
- Products’ consistency-evaluation status, exposure to centralized procurement price cuts, and renewal of the pharmaceutical manufacturing permit due to expire December 31, 2020.
- COVID-19’s subsequent effects on production, distribution, sales and liquidity, beyond the March 2020 update.
- Progress in remediating the material weakness, and reconciliation of the MD&A net-loss and impairment descriptions to the audited statements.